MabVax Raises $5.25M

San Diego-based MabVax Therapeutics, a developer of immunotherapies aimed at preventing recurrent cancer, said today that it has raised $5.25M in a funding round. The round was led by Numoda Capital Innovation, and also included Burrill Capital Fund IV and RTP Venture Fund. MabVax said the funding will go towards its phase 2 vaccine aimed at preventing recurrent sarcoma, as well as an antibody program targeting metastatic pancreatic cancer. More information »